Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer

Samuel Wang, Andrew Lemieux, Jayashree Kalpathy-Cramer, Celine B. Ord, Gary V. Walker, C. David Fuller, Jong Sung Kim, Charles Thomas

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Purpose: Although adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patients, identifying which patients will benefit remains challenging because of the rarity of this disease. The specific aim of this study was to create a decision aid to help make individualized estimates of the potential survival benefit of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. Methods: Patients with resected gallbladder cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database who were diagnosed between 1995 and 2005. Covariates included age, race, sex, stage, and receipt of adjuvant chemotherapy or chemoradiotherapy (CRT). Propensity score weighting was used to balance covariates between treated and untreated groups. Several types of multivariate survival regression models were constructed and compared, including Cox proportional hazards, Weibull, exponential, log-logistic, and lognormal models. Model performance was compared using the Akaike information criterion. The primary end point was overall survival with or without adjuvant chemotherapy or CRT. Results: A total of 1,137 patients met the inclusion criteria for the study. The lognormal survival model showed the best performance. A Web browser-based nomogram was built from this model to make individualized estimates of survival. The model predicts that certain subsets of patients with at least T2 or N1 disease will gain a survival benefit from adjuvant CRT, and the magnitude of benefit for an individual patient can vary. Conclusion: A nomogram built from a parametric survival model from the SEER-Medicare database can be used as a decision aid to predict which gallbladder patients may benefit from adjuvant CRT.

Original languageEnglish (US)
Pages (from-to)4627-4632
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number35
DOIs
StatePublished - Dec 10 2011

Fingerprint

Adjuvant Chemoradiotherapy
Gallbladder Neoplasms
Nomograms
Survival
Decision Support Techniques
Adjuvant Chemotherapy
Medicare
Epidemiology
Web Browser
Databases
Propensity Score
Gallbladder
Logistic Models

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. / Wang, Samuel; Lemieux, Andrew; Kalpathy-Cramer, Jayashree; Ord, Celine B.; Walker, Gary V.; Fuller, C. David; Kim, Jong Sung; Thomas, Charles.

In: Journal of Clinical Oncology, Vol. 29, No. 35, 10.12.2011, p. 4627-4632.

Research output: Contribution to journalArticle

Wang, S, Lemieux, A, Kalpathy-Cramer, J, Ord, CB, Walker, GV, Fuller, CD, Kim, JS & Thomas, C 2011, 'Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer', Journal of Clinical Oncology, vol. 29, no. 35, pp. 4627-4632. https://doi.org/10.1200/JCO.2010.33.8020
Wang, Samuel ; Lemieux, Andrew ; Kalpathy-Cramer, Jayashree ; Ord, Celine B. ; Walker, Gary V. ; Fuller, C. David ; Kim, Jong Sung ; Thomas, Charles. / Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 35. pp. 4627-4632.
@article{f662a58e22354d2999d846a61c955886,
title = "Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer",
abstract = "Purpose: Although adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patients, identifying which patients will benefit remains challenging because of the rarity of this disease. The specific aim of this study was to create a decision aid to help make individualized estimates of the potential survival benefit of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. Methods: Patients with resected gallbladder cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database who were diagnosed between 1995 and 2005. Covariates included age, race, sex, stage, and receipt of adjuvant chemotherapy or chemoradiotherapy (CRT). Propensity score weighting was used to balance covariates between treated and untreated groups. Several types of multivariate survival regression models were constructed and compared, including Cox proportional hazards, Weibull, exponential, log-logistic, and lognormal models. Model performance was compared using the Akaike information criterion. The primary end point was overall survival with or without adjuvant chemotherapy or CRT. Results: A total of 1,137 patients met the inclusion criteria for the study. The lognormal survival model showed the best performance. A Web browser-based nomogram was built from this model to make individualized estimates of survival. The model predicts that certain subsets of patients with at least T2 or N1 disease will gain a survival benefit from adjuvant CRT, and the magnitude of benefit for an individual patient can vary. Conclusion: A nomogram built from a parametric survival model from the SEER-Medicare database can be used as a decision aid to predict which gallbladder patients may benefit from adjuvant CRT.",
author = "Samuel Wang and Andrew Lemieux and Jayashree Kalpathy-Cramer and Ord, {Celine B.} and Walker, {Gary V.} and Fuller, {C. David} and Kim, {Jong Sung} and Charles Thomas",
year = "2011",
month = "12",
day = "10",
doi = "10.1200/JCO.2010.33.8020",
language = "English (US)",
volume = "29",
pages = "4627--4632",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

TY - JOUR

T1 - Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer

AU - Wang, Samuel

AU - Lemieux, Andrew

AU - Kalpathy-Cramer, Jayashree

AU - Ord, Celine B.

AU - Walker, Gary V.

AU - Fuller, C. David

AU - Kim, Jong Sung

AU - Thomas, Charles

PY - 2011/12/10

Y1 - 2011/12/10

N2 - Purpose: Although adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patients, identifying which patients will benefit remains challenging because of the rarity of this disease. The specific aim of this study was to create a decision aid to help make individualized estimates of the potential survival benefit of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. Methods: Patients with resected gallbladder cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database who were diagnosed between 1995 and 2005. Covariates included age, race, sex, stage, and receipt of adjuvant chemotherapy or chemoradiotherapy (CRT). Propensity score weighting was used to balance covariates between treated and untreated groups. Several types of multivariate survival regression models were constructed and compared, including Cox proportional hazards, Weibull, exponential, log-logistic, and lognormal models. Model performance was compared using the Akaike information criterion. The primary end point was overall survival with or without adjuvant chemotherapy or CRT. Results: A total of 1,137 patients met the inclusion criteria for the study. The lognormal survival model showed the best performance. A Web browser-based nomogram was built from this model to make individualized estimates of survival. The model predicts that certain subsets of patients with at least T2 or N1 disease will gain a survival benefit from adjuvant CRT, and the magnitude of benefit for an individual patient can vary. Conclusion: A nomogram built from a parametric survival model from the SEER-Medicare database can be used as a decision aid to predict which gallbladder patients may benefit from adjuvant CRT.

AB - Purpose: Although adjuvant chemoradiotherapy for resected gallbladder cancer may improve survival for some patients, identifying which patients will benefit remains challenging because of the rarity of this disease. The specific aim of this study was to create a decision aid to help make individualized estimates of the potential survival benefit of adjuvant chemoradiotherapy for patients with resected gallbladder cancer. Methods: Patients with resected gallbladder cancer were selected from the Surveillance, Epidemiology, and End Results (SEER) -Medicare database who were diagnosed between 1995 and 2005. Covariates included age, race, sex, stage, and receipt of adjuvant chemotherapy or chemoradiotherapy (CRT). Propensity score weighting was used to balance covariates between treated and untreated groups. Several types of multivariate survival regression models were constructed and compared, including Cox proportional hazards, Weibull, exponential, log-logistic, and lognormal models. Model performance was compared using the Akaike information criterion. The primary end point was overall survival with or without adjuvant chemotherapy or CRT. Results: A total of 1,137 patients met the inclusion criteria for the study. The lognormal survival model showed the best performance. A Web browser-based nomogram was built from this model to make individualized estimates of survival. The model predicts that certain subsets of patients with at least T2 or N1 disease will gain a survival benefit from adjuvant CRT, and the magnitude of benefit for an individual patient can vary. Conclusion: A nomogram built from a parametric survival model from the SEER-Medicare database can be used as a decision aid to predict which gallbladder patients may benefit from adjuvant CRT.

UR - http://www.scopus.com/inward/record.url?scp=83255162611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83255162611&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.8020

DO - 10.1200/JCO.2010.33.8020

M3 - Article

C2 - 22067404

AN - SCOPUS:83255162611

VL - 29

SP - 4627

EP - 4632

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 35

ER -